Medicon Valley Brochure

Medicon Valley Brochure

Spanning eastern Denmark and south-western Sweden, Medicon Valley is home to one of Europe's strongest life science clusters. Brimming with talented academics and researchers it offers a health business environment with an abundance of exciting opportunities for pharma and biotech companies.

Copenhagen Capacity and Invest in Skåne are the official inward investment agencies in the region and can help you finding the right partners and discovering the best investment opportunities.


> READ THE MEDICON VALLEY BROCHURE



The Stockholm Stock Exchange listing committee has approved CellaVision AB for listing on NASDAQ OMX Stockholm, Small Cap

> PRINT THIS PAGE
   SHARE
May 25, 2010

The listing means that the trading in CellaVision shares is moved from the marketplace NASDAQ OMX First North Premier ("First North") to NASDAQ OMX Stockholm. First day of trading is 31 May 2010. The listing of CellaVision's share on First North thereby ceases and last day of trading on First North is on 28 May 2010. The Company's shareholders do not have to take any action in connection with the listing on NASDAQ OMX Stockholm. No issue of new shares is taking place in connection with the listing on NASDAQ OMX Stockholm. The share will be traded under the same ticker as before; CEVI, ISIN-code SE0000683484.

"Since our first year of revenue in 2001, CellaVision has demonstrated strong growth and rising profitability. The listing on NASDAQ OMX Stockholm is part of CellaVision's growth strategy and is made to facilitate for institutional investors to invest in the CellaVision share and creating prerequisites for improved liquidity in the share, which increases the flexibility in the Company's continued expansion. Furthermore, the listing is expected to bring increased attention from customers and partners, the stock market, media and other external stakeholders, thus increasing CellaVision's exposure." says Yvonne Mårtensson, CEO of CellaVision.

A prospectus (in Swedish only) is available at the company website; www.cellavision.com/prospekt. In the prospectus the following financial goals (not previously publicised) for CellaVision are included:

CellaVision's financial target is to grow its revenue with at least 15% per year, on average over a business cycle, with an operating margin exceeding 15%.

For more information, please contact:

CellaVision AB
Lars Gatenbeck
Chairman of the Board
Tel: +46 70 535 44 44
E-mail: lars.gatenbeck@lifeequity.se

Yvonne Mårtensson
CEO
Tel: +46 708 33 77 82
E-mail: yvonne.martensson@cellavision.se

Johan Wennerholm
CFO
Tel: +46 708 33 81 68
E-mail: johan.wennerholm@cellavision.se

Or visit: www.cellavision.se